medigraphic.com
ISSN 1025-0255 (Electronic)

2016, Number 1

<< Back Next >>

AMC 2016; 20 (1)

Mycosis fungoides in tumoral stage: a case report

Junco BM, Betancourt BG, Machado GJL, Larquin CJI

Language: Spanish
References: 17
Page: 44-49
PDF size: 444.25 Kb.


ABSTRACT

Background: mycosis fungoides is a malignant neoplasm that originates in the T-cells. It has a chronic course and it is characterized by lesions that can be maculae (erythematous, hypopigmented and hyperpigmented); papulae; plaques; patches, sometimes poikilodermic; nodules or tumors that can ulcerate and get occasionally to erythroderma. Although it is the most common among cutaneous T-cell lymphomas (44%), it is a rare disease.
Objective: to present the clinical case of a patient with the diagnosis of mycosis fungoides.
Clinical case: a forty-three-year-old male patient who had presented lesions in the skin for three years. Initially, the lesions were described as nodular. These lesions were distributed at the level of the external genitals, in higher number than two dozens and were erythematous, flat and one to two centimeters in diameter. Some of the lesions were in the axillae, face, scalp and dorsum. Erythematous, scaly plaques were found presenting well-defined edges. Some of the plaques were distributed isolated, while others joined to form bigger plaques. A biopsy of the skin lesions was made and proved positive for cutaneous T-cell lymphoma, type mycosis fungoides in tumoral stage.
Conclusion: mycosis fungoides is a rare disease, mainly in the initial stage. It can be wrongly diagnosed as contact dermatitis, psoriasis or atopic dermatitis; that is why it is important to take into account the disease to early diagnose it.


REFERENCES

  1. Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, et al. Topical chemo-therapy in cutaneous T-cell lymphoma: posi-tive results of a randomized, controlled, mul-ticenter trial testing the efficacy and safety of a novel mechlorethamine, 0,02 %, gel in mycosis fungoides. JAMA Dermatol. 2013 Jan;149(1):25-32.

  2. Livingstone I, Ramamurthi S, Drummond S, Kemp E, Roberts F. Corneal perforation due to limbal involvement in Sézary syndrome. Graefes Arch Clin Exp Ophthalmol. 2011 Jul;249(7):1091-4.

  3. Horwitz SM, Kim YH, Foss F, ZAin JM, Myskowski PL, Lechowicz MJ, et al. Identifi-cation of an active, well-tolerated dose of pralatrexate in patients with relapsed or re-fractory cutaneous T-cell lymphoma. Blood. May 2012;119(18):4115-22.

  4. Tsuji H, Wada T, Murakami M, Kashiwagi T, Ito Y, Ishida-Yamamoto A, et al. Two cases of mycosis fungoides treated by reduced-intensity cord blood transplantation. J Der-matol. 2010 Dec;37(12):1040-5.

  5. Gardner JM, Evans KG, Musiek A, Rook AH, Kim EJ. Update on treatment of cutaneous T-cell lymphoma. Curr Opin Oncol. 2009 Mar;21(2):131-7.

  6. Alsaleh QA, Nanda A, Al-Ajmi H, Al-Sabah H, Elkashlan M, Al-Shemmari S, et al. Clini-coepidemiological features of mycosis fun-goides in Kuwait, 1991-2006. Int J Derma-tol. 2010 Dec;49(12):1393-8.

  7. Olsen EA, Rook AH, Zic J. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol. 2011 Feb;64(2):352-404.

  8. van Doorn R, van Kester MS, Dijkman R, Ver-meer MH, Mulder AA, Szuhai K, et al. On-cogenomic analysis of mycosis fungoides re-veals major differences with Sezary syn-drome. Blood. 2009 Jan 1;113(1):127-36.

  9. Kim ST, Sim HJ, Jeon YS, Lee JW, Roh HJ, Choi SY, et al. Clinicopathological features and T-cell receptor gene rearrangement find-ings of mycosis fungoides in patients younger than age 20 years. J Dermatol. 2009 Jul;36(7):392-402.

  10. Agar NS, Wedgeworth E, Crichton S. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Re-search and Treatment of Cancer staging pro-posal. J Clin Oncol. 2010 Nov;28(31):4730-9.

  11. Pileri A, Facchetti F, Rütten A, Zumiani G, Boi S, Fink-Puches R, et al. Syringotropic mycosis fungoides: a rare variant of the disease with peculiar clinicopathologic features. Am J Sug Pathol. 2011 Jan;35(1):100-9.

  12. Pope E, Weitzman S, Ngan B. Mycosis fun-goides in the pediatric population: report from an international Childhood Registry of Cutaneous Lymphoma. J Cutan Med Surg. 2010 Jan-Feb;14(1):1-6.

  13. Massone C, Chott A, Metze D, Kerl K, Citarella L, Vale E, et al. Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lym-phomas of the skin: a morphologic, immuno-phenotypic, and molecular study of 50 pa-tients. Am J Surg Pathol. 2004 Jun;28(6):719-35.

  14. Bi MY, Curry JL, Christiano AM, Hordinsky MK, Norris DA, Price VH, et al. The spectrum of hair loss in patients with mycosis fungoides and Sézary syndrome. J Am Acad Dermatol. 2011 Jan;64(1):53-63.

  15. Muniesa C, Estrach T, Pujol RM, Gallardo F, Garcia-Muret P, Climent J, et al. Follicu-lotropic mycosis fungoides: clinicopathological features and outcome in a series of 20 cases. J Am Acad Dermatol. 2010 Mar;62(3):418-26.

  16. Lange-Asschenfeldt S, Babilli J, Beyer M, Ríus-Diaz F, González S, Stockfleth E, et al. Con-sistency and distribution of reflectance confo-cal microscopy features for diagnosis of cuta-neous T cell lymphoma. J Biomed Opt. 2012 Jan;17(1):016001.

  17. Furmanczyk PS, Wolgamot GM, Kussick SJ, Sabath DE, Olerud JE, Argenyi ZB. Diagnosis of mycosis fungoides with different algorith-mic approaches. J Cutan Pathol. 2010 Jan;37(1):8-14.




2020     |     www.medigraphic.com